Form 4: UTHR CFO Sells Shares Under Pre-Planned 10b5-1 Program

United Therapeutics CFO James Edgemond executed a pre-planned sale of 21,000 common shares following the exercise of stock options.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), reported transactions involving the company's common stock.
• On December 1, 2025, Mr. Edgemond exercised stock options for 21,000 shares of common stock at an exercise price of $146.03 per share.
• Concurrently, he sold 21,000 shares of common stock in multiple transactions at weighted average prices ranging from $477.9783 to $484.68 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 5, 2025.
• Following these transactions, Mr. Edgemond beneficially owns 8,142 shares of common stock directly and 24,517 derivative stock options directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it involves insider selling, the transactions were pre-planned under a Rule 10b5-1 plan, which is a routine event for executive compensation and personal financial management, rather than a reaction to new company-specific news or performance.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, which demonstrates proactive compliance with insider trading regulations and mitigates concerns about opportunistic trading.

Negatives

• The sale of 21,000 shares by a key executive, even if pre-planned, represents a reduction in insider ownership, which can sometimes be perceived as a lack of confidence, though this is often a routine liquidity event.

Risks

• No specific risks were mentioned in the filing beyond the inherent market perception associated with insider selling, which can sometimes lead to minor, short-term negative sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider's past transactions.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for each multi-trade transaction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common occurrence across all industries for executives managing their personal finances and diversifying their portfolios. This specific filing does not provide information to analyze broader industry trends or competitive positioning.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices in corporate governance, demonstrating a commitment to transparency and avoiding accusations of trading on material non-public information. Many public companies encourage or require their executives to use such plans for equity transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a CFO could be viewed neutrally or slightly negatively, but the pre-planned nature under 10b5-1 mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company are mentioned in this Form 4 filing.

Key Dates

Keywords

United Therapeutics, UTHR, James Edgemond, CFO, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, Executive Compensation